NAOV
NanoVibronix, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.90
+1.06%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.7M | 2.6M | 2.3M | 752.0K | 1.7M |
| Cost of Revenue | 1.9M | 1.1M | 746.0K | 585.0K | 925.0K |
| Gross Profit | 806.0K | 1.5M | 1.5M | 167.0K | 770.0K |
| Operating Expenses | |||||
| R&D Expense | 2.1M | 909.0K | 185.0K | 283.0K | 293.0K |
| SG&A Expense | 8.2M | 4.2M | 4.8M | 4.9M | 6.2M |
| General & Admin Expense | 6.1M | 3.5M | 3.9M | 3.9M | 5.1M |
| Selling & Marketing Expense | 2.1M | 720.0K | 864.0K | 965.0K | 1.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 10.3M | 5.1M | 5.0M | 5.2M | 6.5M |
| Cost and Expenses | 12.1M | 6.1M | 5.7M | 5.8M | 7.4M |
| Operating Income (EBIT) | (9.4M) | (3.6M) | (3.4M) | (5.0M) | (5.7M) |
| Non-Operating | |||||
| Interest Income | (22.0K) | 31.0K | — | — | — |
| Interest Expense | 294.0K | 135.0K | 246.0K | 347.0K | — |
| Net Interest Income | (316.0K) | (104.0K) | (246.0K) | (347.0K) | — |
| Other Non-Op Income/Expense | 2.2M | (104.0K) | (246.0K) | (401.0K) | (8.6M) |
| Non-Operating Income (excl Interest) | (2.5M) | 104.0K | 111.0K | 401.0K | 8.6M |
| EBT (Pre-Tax Income) | (7.3M) | (3.7M) | (3.7M) | (5.4M) | (14.3M) |
| Income Tax Expense | 117.0K | 19.0K | 29.0K | 35.0K | 32.0K |
| Bottom Line | |||||
| Net Income | (3.6M) | (3.7M) | (3.7M) | (5.4M) | (14.3M) |
| Earnings from Cont. Ops | (7.4M) | (3.7M) | (3.7M) | (5.4M) | (14.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (5.2M) | (3.7M) | (3.7M) | (5.4M) | (14.3M) |
| Per Share | |||||
| Basic EPS | ($10.34) | ($13.73) | ($21.20) | ($38.40) | ($113.50) |
| Diluted EPS | ($10.34) | ($13.73) | ($21.20) | ($38.40) | ($113.50) |
| Revenue Per Share | $5.54 | $9.48 | $13.04 | $5.30 | $13.47 |
| Shares | |||||
| Basic Shares Outstanding | 484566 | 269848 | 175010 | 141967 | 125814 |
| Diluted Shares Outstanding | 484566 | 269848 | 175010 | 141967 | 125814 |
| Profitability Metrics | |||||
| EBITDA | (6.3M) | (3.7M) | (3.5M) | (5.4M) | (14.2M) |
| D&A | 639.0K | 1.0K | 1.0K | 1.0K | 2.0K |
| EBIT | (7.0M) | (3.7M) | (3.5M) | (5.4M) | (14.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025